The U.S. government is debating whether to renew the U.S.-China Science and Technology Agreement; AstraZeneca plans to break up its business in China and list it separately in Hong Kong; the Italian government applies Golden Power regulations to limit the influence of China's Sinochem on tyremaker Pirelli
British firms in China are concerned about the way China introduces new regulations and the vagueness of its laws; the European Union introduces additional product safety-related requirements for businesses selling products online to domestic consumers; Hong Kong seeks to allow offerors and their concert parties to vote in a shareholders' meeting regarding a firm's privatization.
Hangzhou Court applies copyright and unfair competition law to protect virtual human intellectual property in the absence of specific legal provisions; Hong Kong's loosened cryptocurrency rules attract Chinese state-owned banks; and increased regulatory scrutiny pushes Chinese investment in Europe to an 8-year low
China's new Merger Control Provisions are likely to usher in a period of significant uncertainty for killer acquisitions. HUANG Wei, ZHU Fan, GAO Chang and MIAO Roujia of Tian Yuan Law Firm take a look at the new rules and provide guidance as to how below-threshold transactions with a nexus to China could be approached.
A new and important set of anti-monopoly provisions have come into force in China. Huang Wei, managing partner of Beijing Tian Yuan Law Firm describes how the provisions will work and how foreign companies in China should react
New CSRC rules on overseas listing; China raises concerns over Ford gaining access to Chinese electric battery technology; and CSRC clarifies that it will not impose a blanket ban on mainland investors trading overseas stocks
China has imposed new regulations on PRC companies raising foreign mid-to-long-term debt; It also has introduced stricter measures on bank asset risk classification; and for the first time, it has granted a wholly foreign-owned securities firm permission to be established in China.
2022 regulatory trends in China, including data protection, TMT, capital markets, PE/VC, IP, dispute resolution, healthcare, banking & finance, sanctions and antitrust.
US Congress passes Act to protect American intellectual property; China plans measures to boost foreign investment centrally and locally; and deals in the life sciences sector are subject to strong CFIUS scrutiny.
Nathan Bush, Nicholas Klein, Catherine Pawluch, and Alexandra Kamerling of DLA Piper survey the risks under the Foreign Direct Investment regimes of key jurisdictions, starting with the U.S., Canada, and the U.K. in this two-part series
